TRMT5

Across TCGA pan-cancer cohorts, TRMT5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRMT5 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TRMT5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TRMT5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, BLCA, and LUAD are the cancer types where TRMT5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.622	.005	22	view →
BLCA	DFS	Median	II,III,IV	0.860	0.324	.024	12	view →
LUAD	DFS	Median	All	0.225	0.679	.002	12	view →
LIHC	OS	Median	II,III,IV	0.204	0.715	.016	9	view →
UCS	DFS	Median	All	1.000	0.224	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRMT5–UCEC (DFS)

Open the UCEC breakdown →